improve risk stratification for patients who are perceived as higher risk. To date, no published studies describe treatment patterns for Veterans following use of genomic tests. This study compares treatment patterns before and after introduction of the GPS assay within 6 VAMCs.
METHODS: Men with newly diagnosed, NCCN very low, low, or intermediate risk PCa were eligible. We established treatment patterns in an untested patient cohort by reviewing charts from 2013-2014. From 2015-2016, we introduced the GPS assay within these same VAMCs in a prospective study. Six months after biopsy results, we reviewed charts to establish treatments patterns for both untested and tested Veterans.
RESULTS: There were 200 men in the untested cohort and 190 men in the tested cohort. Patient characteristics were similar across groups. AS increased by 12% overall. The largest increase was among patients under age 60 (33% increase). AS increased in all NCCN risk groups with the largest increases in NCCN low risk (16%) and across racial subgroups (11% Caucasian, 16% Black, 20% Other). Veterans exposed to AO showed a small decrease in AS, while Veterans without exposure showed a 19% increase in AS. Median GPS was similar across racial groups and between Veterans exposed and not exposed to AO.
CONCLUSIONS: In clinically similar cohorts of untested and tested Veterans, implementation of the GPS assay increased use of AS across all age, risk, and racial groups. The assay showed similar biological risk between Caucasians and Blacks and Veterans exposed and not exposed to AO. GPS may be a useful tool to refine risk assessment of PCa and to increase the already high rates of AS among clinically and biologically low risk patients, regardless of their race and AO exposure. Future studies of Black and AO exposed Veterans, including persistence on AS, are needed confirm these findings. Accurate cancer staging is critical for predicting prognosis and defining optimal treatments. Cancer stages are defined by the American Joint Committee on Cancer (AJCC) which produces and updates the evidence-based Cancer Staging Manual (CSM). In October, 2016 the AJCC released the CSM 8th edition, which is effective for all cancer cases diagnosed on or after January 1, 2017. The aim of this project is to provide a summary of the changes to the classification of these cancers of the urinary tract.
METHODS: To update the CSM 8th Edition, the AJCC convened an international multispecialty expert panel of leading cancer physicians, population scientists, cancer registrars and statisticians. TNM cancer classification is based primarily on anatomic information regarding extent of the primary tumor (T), regional lymph node status (N), and presence of distant metastases (M). Changes in TNM classification were made by the panel after evidence review and expert consensus. The AJCC Evidence-Based Medicine and Statistics Core determined levels of evidence (1 to 4) for each change through analysis of the number and quality of studies used in decision-making.
RESULTS: CSM 8th Edition changes in urinary tract cancers are detailed in table 1. In summary, the T3a definition for kidney cancer was modified to include tumors invading the pelvicalyceal system. For cancer of the renal pelvis and ureter, prior categorization of N3 metastasis was collapsed into the N2 category. Changes in bladder cancer staging included reclassification of perivesical lymph node involvement, sub-classification of distant metastases and addition of prognostic subgroups for stages 3 and 4. For urethral cancer, urothelial carcinoma in situ of the prostate was collapsed into single stage (Tis), clarification was made for T1 and T4 disease, and distinction was made between N1 and N2 disease.
CONCLUSIONS: The AJCC CSM reflects the latest evidence and expert consensus for cancer staging. The 8th Edition refines the TNM classifications of urinary tract cancers and represents a further step toward a personalized approach to cancer staging. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1163
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